Despite showing strength in February, lab stocks struggled in March—down 16 percent over five weeks and down 11 percent over 13 weeks for the week ended March 20, 2009. The 14 publicly traded labs tracked by the G-2 Reports Laboratory Stock Index are down 7 percent so far this year. The Nasdaq and S&P 500 Indices also continue to struggle. For 2009, the Nasdaq is down over 10.72 percent, and the S&P 500 remains down over 17 percent so far in the year.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

April 2009 - Table of Contents

LIR April 2009 (full PDF issue)

Economic Stimulus Bill’s $19 Billion in IT Investments Include Incentives for Pathologists, but Not Labs

California AG Alleges Billing Fraud in Suit Against Quest, LabCorp, and Five Other Labs

Survey Finds 63% of Labs Grappling With High Vacancy Rates; Medical Technologist Rate Highest at Over 10%

Genoptix Leads in FY2008 Productivity Benchmark Measures

Inside the Lab Industry: Stimulus Bill’s $19 Billion in IT Investment Provides Incentives, Penalties for Lab Industry

Cleveland Clinic Eyes $25 Million Reference Lab Expansion, Broadens Focus on Cardiac Esoteric Testing

Genoptix FY08 Revenues Up 96% to $116 Million; Growth Includes Move Into Solid Tumor Testing

Enzo Biochem Names New Clinical Lab President; Acquires Assay Designs

Lab Stocks Down 16% So Far in March; Down 7% So Far in 2009

LabCorp, Quest Name New Chief Medical Officers